Stevanato Group S.p.A. (NYSE: STVN) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
21.70
-0.97-4.28%
TA
Loading chart...
Snapshot
| Index | - | P/E | 38.75 | EPS (ttm) | 0.56 | Insider Own | 0.24% | Shs Outstand | 273.01M | Perf Week | 3.83% |
| Market Cap | 5.92B | Forward P/E | 25.28 | EPS next Y | 0.86 | Insider Trans | -2.15% | Shs Float | 273.01M | Perf Month | -0.05% |
| Enterprise Value | 6.33B | PEG | 2.05 | EPS next Q | 0.20 | Inst Own | - | Short Float | 0.41% | Perf Quarter | 23.72% |
| Income | 157.00M | P/S | 4.16 | EPS this Y | 27.40% | Inst Trans | - | Short Ratio | 2.81 | Perf Half Y | 43.05% |
| Sales | 1.43B | P/B | 3.35 | EPS next Y | 20.34% | ROA | 5.13% | Short Interest | 1.13M | Perf YTD | 7.85% |
| Book/sh | 6.48 | P/C | 62.36 | EPS next 5Y | 18.87% | ROE | 8.94% | 52W High | 28.00 -22.50% | Perf Year | -19.42% |
| Cash/sh | 0.35 | P/FCF | - | EPS past 3/5Y | -0.27% 11.60% | ROIC | 6.36% | 52W Low | 12.89 68.35% | Perf 3Y | -25.15% |
| Dividend Est. | 0.06 (0.29%) | EV/EBITDA | 19.91 | Sales past 3/5Y | 7.51% 11.22% | Gross Margin | 29.16% | Volatility | 5.45% 4.06% | Perf 5Y | -18.27% |
| Dividend TTM | 0.06 (0.29%) | EV/Sales | 4.44 | EPS Y/Y TTM | 20.37% | Oper. Margin | 16.08% | ATR (14) | 0.90 | Perf 10Y | - |
| Dividend Ex-Date | Jun 11, 2026 | Quick Ratio | 1.08 | Sales Y/Y TTM | 19.35% | Profit Margin | 10.99% | RSI (14) | 54.58 | Recom | 2.38 |
| Dividend Gr. 3/5Y | 6.61% - | Current Ratio | 1.61 | EPS Q/Q | 33.33% | SMA20 | 1.08% | Beta | 0.74 | Target Price | 26.00 |
| Payout | 0.04% | Debt/Eq | 0.32 | Sales Q/Q | 10.73% | SMA50 | 4.66% | Rel Volume | 0.70 | Prev Close | 22.67 |
| Employees | 6,010 | LT Debt/Eq | 0.23 | Earnings | Nov 05 | SMA200 | 18.74% | Avg Volume | 379.93K | Price | 21.70 |
| IPO Date | Jul 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 8.75% -0.34% | Net Debt/EBITDA | 1.34 | Volume | 265,531 | Change | -4.28% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-05-26 | Reiterated | Keybanc | Overweight | $32 |
| Feb-10-26 | Reiterated | Jefferies | Hold | $23 → $18 |
| Aug-07-24 | Reiterated | Citigroup | Buy | $28 |
| Nov-01-23 | Downgrade | Jefferies | Buy → Hold | |
| Sep-26-23 | Reiterated | Stephens | $33 | |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal Weight | |
| Jan-06-23 | Reiterated | Morgan Stanley | Overweight | $22 |
| Apr-25-22 | Reiterated | Wells Fargo | Overweight | $19 |
Latest News· Times ET
Sep-15-26
Sep-15-2601:01PM
Sep-11-26
Sep-08-26
Sep-04-26
Sep-01-26
Sep-01-2604:00PM
Aug-29-26
Aug-28-26
Aug-28-2604:08PM
Aug-11-26
Aug-10-26
Aug-09-26
Aug-05-26
Aug-04-26
04:51AM
02:30AM
Jul-30-26
Company
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,425 | 1,285 | 1,194 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,009 | 913 | 867 | — | — | — | — | — | |
| Gross Profit | 415 | 373 | 327 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 148 | 139 | 128 | — | — | — | — | — | |
| Research and Development | 30 | 28 | 34 | — | — | — | — | — | |
| Other Operating Expense | 8 | -1 | -9 | — | — | — | — | — | |
| Operating Income | 229 | 207 | 174 | — | — | — | — | — | |
| Interest Expense | 10 | 25 | 7 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | 23 | 7 | — | — | — | — | — | |
| Net Income Before Taxes | 223 | 205 | 173 | — | — | — | — | — | |
| Income Taxes | 67 | 53 | 46 | — | — | — | — | — | |
| Consolidated Net Income | 157 | 151 | 127 | — | — | — | — | — | |
| Net Income From Continuing Operations | 157 | 151 | 127 | — | — | — | — | — | |
| Net Income | 157 | 151 | 127 | — | — | — | — | — | |
| EPS (Recurring) | 0.56 | 0.55 | 0.47 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.56 | 0.55 | 0.47 | — | — | — | — | — | |
| EPS (Diluted) | 0.56 | 0.55 | 0.47 | — | — | — | — | — | |
| EBITDA | 318 | 326 | 268 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 38.75 | 36.40 | 46.84 | — | — | — | — | — | |
| Price To Sales Ratio | 4.16 | 4.27 | 4.98 | — | — | — | — | — | |
| Gross Margin | 29.12 | 29.03 | 27.39 | — | — | — | — | — | |
| Operating Margin | 16.07 | 16.11 | 14.57 | — | — | — | — | — | |
| Net Margin | 11.02 | 11.75 | 10.64 | — | — | — | — | — | |
| Shares Outstanding | 273 | 273 | 273 | — | — | — | — | — | |
| Market Capitalization | 5,924 | 5,493 | 5,949 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Santel Luciano | Director | Aug 07 '26 | Sale | 20.09 | 2,023 | 40,642 | 4,739 | Aug 10 |
| Dal Lago Marco | Chief Financial Officer | Aug 07 '26 | Sale | 20.09 | 4,209 | 84,559 | 81,144 | Aug 10 |
| Magistretti Elisabetta | Director | Aug 07 '26 | Sale | 20.09 | 2,045 | 41,084 | 2,930 | Aug 10 |
| FEDERICI WILLIAM J | Director | Jun 15 '26 | Sale | 17.09 | 1,493 | 25,515 | 26,991 | Jun 26 |
| Balachandran Madhavan | Director | Jun 15 '26 | Sale | 17.09 | 1,493 | 25,515 | 69,458 | Jun 26 |
| MOREL DONALD E JR | Director | Jun 15 '26 | Sale | 17.09 | 1,493 | 25,515 | 37,424 | Jun 26 |
| Flynn Karen | Director | Jun 15 '26 | Sale | 17.09 | 1,493 | 25,515 | 5,757 | Jun 26 |
| Dal Lago Marco | Chief Financial Officer | Jun 12 '26 | Option Exercise | 0.00 | 15,994 | 0 | 85,353 | Jun 26 |
| Stocchi Mauro | See Remarks | Jun 09 '26 | Option Exercise | 0.00 | 13,172 | 0 | 413,629 | Jun 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.